|
 |
|
|||||||
|
|||||||||
Copyright © ERS Journals Ltd 1997
Clinical Trial |
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency
Salmeterol and formoterol are two long-acting beta2-agonists for inhalation, currently being used in clinical practice. The aim of the present study was to investigate the onset of action, duration of effect and potency of these two beta2-agonists in asthmatic patients. Patients (n=28) were included on the basis of salbutamol stepwise reversibility (100, 100 and 200 microg, given cumulatively; total reversibility > or =15%). In a double-blind placebo-controlled crossover study, the bronchodilating properties of formoterol 6, 12 and 24 microg were compared with the effects of salmeterol 50 microg. Formoterol was given via Turbuhaler and salmeterol via Diskhaler, and forced expiratory volume in one second (FEV1) was monitored during 12 h. Formoterol at all doses had a more rapid onset than salmeterol as judged from bronchodilation at 3 min after the dose. Formoterol at all doses had a similar duration of effect to salmeterol 50 microg, as judged from bronchodilation at 12 h after dose administration. When the relative potency of the two drugs was compared, salmeterol 50 microg was estimated to correspond to formoterol 9 microg (95% confidence interval: 3-19 microg). We confirm that formoterol and salmeterol are both long-acting beta2-agonists, but with some differences in effect profile. We confirm the more rapid onset of action of formoterol compared with salmeterol, and furthermore, no difference in duration of effect is evident.
This article has been cited by other articles:
|
|
 |
|
  A. R. Rubinfeld, R. Scicchitano, A. Hunt, P. J. Thompson, A. Van Nooten, and O. Selroos Formoterol Turbuhaler as reliever medication in patients with acute asthma Eur. Respir. J., April 1, 2006; 27(4): 735 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Parsons and J. G. Mastronarde Exercise-Induced Bronchoconstriction in Athletes Chest, December 1, 2005; 128(6): 3966 - 3974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vogelmeier, A. D'Urzo, R. Pauwels{dagger}, J. M. Merino, M. Jaspal, S. Boutet, I. Naya, and D. Price Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J., November 1, 2005; 26(5): 819 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jenkins Formoterol as relief medication in asthma: the jury is still out Eur. Respir. J., November 1, 2003; 22(5): 723 - 724. [Full Text] [PDF]
|
|
|
|
|
|
U. G. Lalloo, J. Malolepszy, D. Kozma, K. Krofta, J. Ankerst, B. Johansen, and N. C. Thomson Budesonide and Formoterol in a Single Inhaler Improves Asthma Control Compared With Increasing the Dose of Corticosteroid in Adults With Mild-to-Moderate Asthma Chest, May 1, 2003; 123(5): 1480 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.W. Ind, C. Villasante, R.J. Shiner, A. Pietinalho, N.G. Boszormenyi, S. Soliman, and O. Selroos Safety of formoterol by Turbuhaler(R) as reliever medication compared with terbutaline in moderate asthma Eur. Respir. J., October 1, 2002; 20(4): 859 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Price, D Dutchman, A Mawson, B Bodalia, S Duggan, and P Todd Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose Thorax, September 1, 2002; 57(9): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Hanania, A. Sharafkhaneh, R. Barber, and B. F. Dickey {beta}-Agonist Intrinsic Efficacy: Measurement and Clinical Significance Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1353 - 1358. [Full Text] [PDF]
|
|
|
|
|
|
K. Richter, S. Janicki, R.A. Jorres, and H. Magnussen Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Eur. Respir. J., May 1, 2002; 19(5): 865 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Nightingale, D. F. Rogers, and P. J. Barnes Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma* Chest, May 1, 2002; 121(5): 1401 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.I. Ketchell, M.W. Jensen, D. Spina, and B.J. O'Connor Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine Eur. Respir. J., April 1, 2002; 19(4): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Malolepszy, G. Boszormenyi Nagy, O. Selroos, P. Larsson, and R. Brander Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction Eur. Respir. J., December 1, 2001; 18(6): 928 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]
|
|
|
|
|
|
H J van der Woude, T H Winter, and R Aalbers Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting {beta}2 agonists Thorax, July 1, 2001; 56(7): 529 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.C. Grootendorst, P.J. Sterk, and H.G.M. Heijerman Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma Eur. Respir. J., March 1, 2001; 17(3): 374 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. PALMQVIST, T. IBSEN, A. MELLÉN, and J. LÖTVALL Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 244 - 249. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |